Literature DB >> 35698468

A Rare Case of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis Obscured by Alkalosis.

Daniel A Fernandez Felix1,2, Gloriana Madrigal Loria1,2, Sapna Sharma1,2, Shorabh Sharma1,2, Carlos E Arias Morales1,2.   

Abstract

Empagliflozin-induced euglycemic diabetic ketoacidosis is a life-threatening metabolic complication of diabetes mellitus characterized by metabolic acidosis, ketonemia, and relatively normal serum glucose levels. We present a rare case of empagliflozin-induced diabetic ketoacidosis obscured by alkalosis. This case report aims to create awareness among clinicians about this entity and consider this diagnosis in their differential, especially in patients taking sodium-glucose co-transporter (SGLT-2) inhibitors who present to the hospital with unspecific symptoms that may not suggest DKA.
Copyright © 2022, Fernandez Felix et al.

Entities:  

Keywords:  alkalosis; diabetic keto-alkalosis; diabetic ketoacidosis (dka); euglycemic diabetic ketoacidosis; sodium glucose co-transporter 2 inhibitors (sglt2i)

Year:  2022        PMID： 35698468      PMCID： PMC9186101          DOI： 10.7759/cureus.25818

Source DB:  PubMed          Journal:  Cureus        ISSN： 2168-8184


  11 in total

Review 1.  SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.

Authors:  Ronald M Goldenberg; Lori D Berard; Alice Y Y Cheng; Jeremy D Gilbert; Subodh Verma; Vincent C Woo; Jean-François Yale
Journal:  Clin Ther       Date:  2016-12       Impact factor: 3.393

2.  Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.

Authors:  Caroline Bonner; Julie Kerr-Conte; Valéry Gmyr; Gurvan Queniat; Ericka Moerman; Julien Thévenet; Cédric Beaucamps; Nathalie Delalleau; Iuliana Popescu; Willy J Malaisse; Abdullah Sener; Benoit Deprez; Amar Abderrahmani; Bart Staels; François Pattou
Journal:  Nat Med       Date:  2015-04-20       Impact factor: 53.440

3.  Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology.

Authors:  A Pfützner; D Klonoff; L Heinemann; N Ejskjaer; J Pickup
Journal:  Endocrine       Date:  2017-03-17       Impact factor: 3.633

Review 4.  Hyperglycemic crises in adult patients with diabetes.

Authors:  Abbas E Kitabchi; Guillermo E Umpierrez; John M Miles; Joseph N Fisher
Journal:  Diabetes Care       Date:  2009-07       Impact factor: 17.152

5.  Rare presentations of ketoacidosis: diabetic ketoalkalosis and ketoacidosis secondary to fasting and muscular dystrophy.

Authors:  Mads Vandsted Svart; Thomas Schmidt Voss; Michael Bayat; Lene Ring Madsen; Lone Thing Andersen; Per Løgstrup Poulsen; Niels Møller
Journal:  Clin Diabetes       Date:  2015-01

6.  The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin.

Authors:  Nellowe Candelario; Jedrzej Wykretowicz
Journal:  Oxf Med Case Reports       Date:  2016-07-27

7.  Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin.

Authors:  Junichiro Adachi; Yuusuke Inaba; Chisato Maki
Journal:  Intern Med       Date:  2017-01-15       Impact factor: 1.271

8.  Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis.

Authors:  Gretchen M Ray; Chelsea Rodriguez; Samantha M Schulman; Preeyaporn Sarangarm; Michelle Bardack; Matthew F Bouchonville
Journal:  Clin Pract Cases Emerg Med       Date:  2019-03-05

9.  Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors.

Authors:  Wataru Ogawa; Kazuhiko Sakaguchi
Journal:  J Diabetes Investig       Date:  2015-09-06       Impact factor: 4.232

10.  Euglycemic Diabetic Ketoacidosis in a Patient with Cocaine Intoxication.

Authors:  Asma Abu-Abed Abdin; Muhammad Hamza; Muhammad S Khan; Awab Ahmed
Journal:  Case Rep Crit Care       Date:  2016-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.